95 related articles for article (PubMed ID: 15245777)
21. Molecular basis of therapeutic approaches to gastric cancer.
Wu K; Nie Y; Guo C; Chen Y; Ding J; Fan D
J Gastroenterol Hepatol; 2009 Jan; 24(1):37-41. PubMed ID: 19196394
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.
Bastian PJ; Ellinger J; Wellmann A; Wernert N; Heukamp LC; Müller SC; von Ruecker A
Clin Cancer Res; 2005 Jun; 11(11):4097-106. PubMed ID: 15930345
[TBL] [Abstract][Full Text] [Related]
23. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
[TBL] [Abstract][Full Text] [Related]
24. Concomitant overexpression of cyclooxygenase-2 in HER-2-positive on Smad4-reduced human gastric carcinomas is associated with a poor patient outcome.
Okano H; Shinohara H; Miyamoto A; Takaori K; Tanigawa N
Clin Cancer Res; 2004 Oct; 10(20):6938-45. PubMed ID: 15501972
[TBL] [Abstract][Full Text] [Related]
25. Molecular markers of prostate cancer outcome.
Quinn DI; Henshall SM; Sutherland RL
Eur J Cancer; 2005 Apr; 41(6):858-87. PubMed ID: 15808955
[TBL] [Abstract][Full Text] [Related]
26. Cytogenetic and molecular aspects of gastric cancer: clinical implications.
Panani AD
Cancer Lett; 2008 Aug; 266(2):99-115. PubMed ID: 18381231
[TBL] [Abstract][Full Text] [Related]
27. Loss of FHIT expression in breast cancer is correlated with poor prognostic markers.
Arun B; Kilic G; Yen C; Foster B; Yardley DA; Gaynor R; Ashfaq R
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1681-5. PubMed ID: 16030101
[TBL] [Abstract][Full Text] [Related]
28. Effects of p53 or p27 overexpression on cyclooxygenase-2 gene expression in head and neck squamous cell carcinoma cell lines.
Lee DW; Park SW; Park SY; Heo DS; Kim KH; Sung MW
Head Neck; 2004 Aug; 26(8):706-15. PubMed ID: 15287038
[TBL] [Abstract][Full Text] [Related]
29. Molecular therapy of head and neck cancer.
Modjtahedi H
Cancer Metastasis Rev; 2005 Jan; 24(1):129-46. PubMed ID: 15785877
[TBL] [Abstract][Full Text] [Related]
30. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention.
Kashfi K; Rigas B
Biochem Pharmacol; 2005 Oct; 70(7):969-86. PubMed ID: 15949789
[TBL] [Abstract][Full Text] [Related]
31. COX-2 and its inhibition as a molecular target in the prevention and treatment of lung cancer.
Liao Z; Milas L
Expert Rev Anticancer Ther; 2004 Aug; 4(4):543-60. PubMed ID: 15270659
[TBL] [Abstract][Full Text] [Related]
32. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma.
Mendrzyk F; Korshunov A; Benner A; Toedt G; Pfister S; Radlwimmer B; Lichter P
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2070-9. PubMed ID: 16609018
[TBL] [Abstract][Full Text] [Related]
33. Suppression of gastric cancer cell growth by targeting the beta-catenin/T-cell factor pathway.
Dvory-Sobol H; Sagiv E; Liberman E; Kazanov D; Arber N
Cancer; 2007 Jan; 109(2):188-97. PubMed ID: 17149756
[TBL] [Abstract][Full Text] [Related]
34. Cyclooxygenase-2 is an independent prognostic factor in gastric carcinoma patients receiving adjuvant chemotherapy and is not associated with EBV infection.
Park ES; Do IG; Park CK; Kang WK; Noh JH; Sohn TS; Kim S; Kim MJ; Kim KM
Clin Cancer Res; 2009 Jan; 15(1):291-8. PubMed ID: 19118057
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of cyclooxygenase-2 and tumor angiogenesis in human gastric cancer.
Koga T; Shibahara K; Kabashima A; Sumiyoshi Y; Kimura Y; Takahashi I; Kakeji Y; Maehara Y
Hepatogastroenterology; 2004; 51(60):1626-30. PubMed ID: 15532792
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in conventional and molecular prognostic factors for gastric carcinoma.
Nitti D; Mocellin S; Marchet A; Pilati P; Lise M
Surg Oncol Clin N Am; 2008 Jul; 17(3):467-83, vii. PubMed ID: 18486878
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of EGFR, p53 and E-cadherin in mucoepidermoid cancer of the salivary glands: a retrospective case series.
Hoyek-Gebeily J; Nehmé E; Aftimos G; Sader-Ghorra C; Sargi Z; Haddad A
J Med Liban; 2007; 55(2):83-8. PubMed ID: 17685120
[TBL] [Abstract][Full Text] [Related]
38. Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer.
Aung PP; Oue N; Mitani Y; Nakayama H; Yoshida K; Noguchi T; Bosserhoff AK; Yasui W
Oncogene; 2006 Apr; 25(17):2546-57. PubMed ID: 16331256
[TBL] [Abstract][Full Text] [Related]
39. Cyclooxygenase-2 induction and prostaglandin E2 accumulation in squamous cell carcinoma as a consequence of epidermal growth factor receptor activation by imatinib mesylate.
Johnson FM; Yang P; Newman RA; Donato NJ
J Exp Ther Oncol; 2004 Dec; 4(4):317-25. PubMed ID: 15844661
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the prognostic value of a panel of tissue tumor markers and established clinicopathological factors in patients with gastric cancer.
Wiksten JP; Lundin J; Nordling S; Kokkola A; Haglund C
Anticancer Res; 2008; 28(4C):2279-87. PubMed ID: 18751407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
